iRhythm Technologies Inc. has released its latest investor presentation, highlighting significant achievements and growth metrics. The company reported a 26.1% increase in revenue for the second quarter of 2025, reaching $186.7 million compared to the same period in 2024. The presentation also revealed that iRhythm has posted over 10 million patient reports since its inception, with more than 2.5 billion hours of curated ECG data collected up to 2024. The company maintains over 30% penetration in the U.S. ambulatory cardiac monitoring market as of December 31, 2024. International market opportunities are emphasized, with a target market of over 5 million tests across prioritized EU and APAC regions. Additionally, iRhythm holds more than 70% market share in long-term continuous monitoring within the U.S. market. The company continues to expand its international presence with early commercial launches in Switzerland, Austria, Netherlands, Spain, and Japan. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.